![Ivonescimab topped Pembrolizumab in beating lung cancer](https://worldschooloflifesciencesip.com/wp-content/uploads/2024/09/pexels-karolina-grabowska-4210559-scaled.jpg)
Has Akeso’s Ivonescimab topped Pembrolizumab® in beating lung cancer?
Ivonescimab (SMT112, AK112), a first-in-class, humanized, tetravalent PD-1/VEGF bispecific monoclonal antibody, being internally developed by Akeso Biopharma (a China-based commercial-stage biopharmaceutical company), has shown exceptional results in